Foundayo vs Wegovy Pill: Oral GLP-1 Scripts Hit New Highs

What Did the Latest Oral GLP-1 Prescription Data Show?

On 4 September 2026, Fierce Pharma's recurring Oral GLP-1 Tracker reported the newest weekly US prescription figures for the two licensed oral GLP-1 tablets on the market, sourced from IQVIA retail-pharmacy data.[1] Novo Nordisk's Wegovy pill (oral semaglutide) recorded approximately 181,000 weekly prescriptions, up 3% week-on-week, while Eli Lilly's Foundayo (orforglipron) recorded approximately 44,000 weekly prescriptions, up 8%.[1] Both figures were the highest either drug had reached since launch.[1]

Neither number represents a clinical result or a regulatory action — both are commercial dispensing metrics for medicines that were already approved earlier in 2026. They are reported here as third-party market data on the licensed pharmaceutical GLP-1 class, distinct from the investigational, injectable research peptides covered elsewhere on this site.

How Did Foundayo and Wegovy Pill Get Here?

Novo Nordisk's Wegovy pill (oral semaglutide 25mg) was FDA-approved in December 2025 on the strength of the Phase 3 OASIS 4 trial, and launched in the US in early January 2026 — giving it roughly a three-month first-mover advantage as the first oral GLP-1 approved for chronic weight management.[2] Eli Lilly's Foundayo (orforglipron), a non-peptide small molecule, followed with FDA approval on 1 April 2026, becoming available through LillyDirect from 6 April and through broader US retail pharmacies and telehealth providers shortly after.[3] Our MHRA approval guide covers Foundayo's later, separate 10 August 2026 UK authorisation.

Growth since launch has been steady rather than explosive for Foundayo. By early August 2026, roughly 20 weeks after its US debut, weekly scripts had just crossed 40,000 (40,862), with analysts at the time floating full-year 2026 US prescription volumes above five million on an annualised basis.[4] The move to ~44,000 by early September continues that trajectory, though Foundayo still trails Wegovy pill by a wide margin in absolute weekly volume.

Why Does the Oral GLP-1 Race Matter for Incretin Research?

Both tablets target the GLP-1 receptor alone, the same pathway that anchors the single-, dual- and triple-agonist peptide research landscape tracked on this site. Their commercial trajectories are a useful, independently reported signal of how quickly the licensed incretin market is scaling: two competing oral formats, approved four months apart, both still climbing toward their highest weekly volumes nine and five months after launch respectively.[1] That sustained commercial demand is part of why receptor-agonism research — including in in vitro work on GLP-1, GIP and glucagon receptor pathways — has continued to attract investment and publication volume through 2026, as covered in our 2026 peptide research landscape overview.

It is worth being precise about what this data does and does not represent. Prescription counts describe dispensing volume for approved medicines under physician prescription and pharmacy fulfilment — they say nothing about efficacy, safety comparisons, or research applications, and they are not a proxy for research-grade compound demand. Retatrutide, by contrast, has no oral formulation, no FDA or MHRA approval, and remains confined to Eli Lilly's investigational TRIUMPH Phase 3 programme, as detailed in our retatrutide approval timeline.

Does This Affect Retatrutide or UK Research-Reagent Supply?

No. This is US retail-pharmacy prescription-volume data for two branded, licensed medicines, reported by a trade press outlet and sourced from a commercial data provider (IQVIA). It has no bearing on the separate Human Medicines Regulations 2012 framework under which unlicensed compounds are lawfully supplied for in vitro research use in the UK. Retatrutide's own regulatory position is unchanged: it remains an investigational, injectable, triple-receptor peptide with no marketing authorisation of any kind, tracked in our retatrutide research overview.

What this data does confirm is that the licensed oral incretin segment — now including oral Wegovy and Foundayo in the US, plus Foundayo's separate UK approval — continues to expand in parallel with, and entirely independently of, the investigational research-peptide pipeline that Velox Peptides' catalogue supports.

Velox Peptides does not stock orforglipron (Foundayo) or semaglutide (Wegovy). These are licensed prescription medicines discussed here for research-news context only. This compound is supplied as a research reagent only, has not been evaluated by the MHRA or FDA for use in our products, and is not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions